Cantor Fitzgerald initiated coverage of AbbVie with an Overweight rating and $200 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- 3 Best Value Stocks to Buy in May 2024, According to Analysts
- AbbVie, Gilgamesh Pharmaceuticals to co-develop psychiatric disorder therapies
- Genmab reports Q1 revenue increased 46% vs. last year
- AbbVie price target lowered to $180 from $195 at BMO Capital
- AbbVie price target lowered to $191 from $196 at Morgan Stanley